Company intelligence / Profile preview

Kincell Bio

Gainesville, Florida, USAkincellbio.com ↗

Ownership: Private
Employees: ~44
Development stage: Other

Overview

Kincell Bio does not have its own clinical results as it does not develop proprietary therapeutics. It has rapidly established itself as a leading CDMO partner by supporting early-stage to late-stage clinical supply and commercialization of advanced immune cell therapies. The company has raised significant funding ($36M in July 2023; $22M in May 2025) to expand its cGMP capabilities and process development services.

Modalities: Autologous CAR-T cell therapiesAllogeneic CAR-T cell therapiesCAR-NK cell therapiesCAR-M (macrophage) cell therapies
Industry: Contract Manufacturing Organization

Partnerships

Partnerships with viral vector/plasmid DNA suppliers

Beyond the preview

Go deeper on Kincell Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kincell Bio.

Explore the full profile